PhaseI/II study of TS-1+CDDP in combination with Radiotherapy with unresectable and locally advanced for biliary tract cancer
Not Applicable
Recruiting
- Conditions
- Biliary tract cancer
- Registration Number
- JPRN-UMIN000007473
- Lead Sponsor
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
(1) bowel movement control is difficult, because of watery diarrhea and chronic diarrhea. (2) administered flucytosine, Phenytoin, Warfarin potassium (3) Pleural effusion or ascitic fluid accumulates (4) with clinically important infection (5) has active carcinoma except carcinoma in situ (6) with gastrointestinal active ulcer (7) sever complication (Heart failure, renal failure, liver failure, Intestinal paralysis, uncontrollable diabetes etc) (8) severe mental disorder (9) severe drug allergy (10) pregnant women or during the nursing, women who like be pregnant and willing to get pregnant, men who want his partner to be pregnant (11) doctor's decision not to be registered to this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method [Phase I] Estimate the maximum tolerated dose (MTD) and recommended dose (RD) [Phase II] Progression free survival (PFS)
- Secondary Outcome Measures
Name Time Method [Phase I] Response Rate, Adverse events [Phase II] Overall survival, Response Rate (RR), Resectable rate, Limited operation rate, adverse events